Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

r of this year.
  • Improved the balance sheet by retiring $17.0 million out of the total $22.0 million principle amount of outstanding convertible notes. These notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the early retirement, Novavax paid 70% of the principal plus accrued and unpaid interest, or $12.1 million, in cash and issued 2,040,000 shares of its common stock for the remaining 30% of the principal, valued in the transaction as approximately $5.1 million. The remaining $5.0 million in outstanding convertible notes will be due on July 15, 2009 and can be paid up to 50% in stock at maturity at Novavax's option.
  • Increased liquidity by raising $11.0 million from sale of 12.5 million shares of common stock to a wholly owned subsidiary of Cadila Pharmaceuticals and raising approximately $7.5 million from the sale of approximately 3.1 million shares of common stock under the sales agreement with Wm Smith & Co.

  • "We are pleased with the significant clinical, corporate, and financial progress we have made in the past few months," said Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. "We have made substantial progress in advancing our VLP based influenza vaccines over the past three years. The recent emergence of the novel influenza A (H1N1) virus highlights the potential value of our recombinant VLP technology as we can produce a genetically matched vaccine to the outbreak strain in about half the time of traditional vaccine technologies. We are in communication with governments and health authorities around the world and will help in any way possible. With the improvement in our financial position, we are in a much stronger position to continue development of our vaccine pipeline and pursue partnerships."

    The anticipated milestones for the remainder of 2009 include:

    <
    '/>"/>
    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
    2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
    3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
    4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
    5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
    6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
    9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
    10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
    11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Bill Jacobs Automotive, a group of ... teaming up with the Heartland Blood Center and offering free ... The drive takes place Saturday, Jan. 18 at the Bill ... p.m. (Photo: http://photos.prnewswire.com/prnh/20140115/MN46637 )  The ...
    (Date:1/15/2014)... FALLS, N.Y., Jan. 15, 2014   Niagara Thermal Products ... selected by Buffalo BioBlower Technologies LLC ("B3") as the ... Phase 2 award from the Army Corps of Engineers.  ... that kills all biological contaminants and destroys VOCs and ...
    (Date:1/15/2014)... (PRWEB) January 15, 2014 Cynvenio, a ... management through the genomic analysis of tumor cells in ... Finder™, a web-based cancer decision support application powered by ... with Cynvenio’s ClearID™ genomic test, Therapy Finder will provide ...
    (Date:1/15/2014)... Jan. 15, 2014 ­ RedBrick Health , a ... technology, today announces that EmblemHealth , the ... company, is now providing the RedBrick Compass health assessment, ... to all of its members. EmblemHealth is among the ...
    Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3
    ... not just because they sparkle. Engineers and physicists ... is as hard as an ice ball to the ... making it an ideal material or coating for seals, ... Carpick, associate professor in the Department of Mechanical Engineering ...
    ... Physicists at UC Riverside have made an accidental ... change how information in computers can be transported ... a property electrons possess that makes them behave ... the development of spin-based semiconductor technology such as ...
    ... Inc.,(Nasdaq: RDYN ) today announced that it has ... Ltd. for faropenem medoxomil (faropenem).,In conjunction with this decision, ... agreement with Asubio Pharma Co., Ltd. and Nippon,Soda Co. ... as a,result of the Company being unable to secure ...
    Cached Biology Technology:University of Pennsylvania engineers reveal what makes diamonds slippery at the nanoscale 2Discovery by UC Riverside physicists could enable development of faster computers 2Discovery by UC Riverside physicists could enable development of faster computers 3Replidyne Terminates Faropenem Agreements 2Replidyne Terminates Faropenem Agreements 3
    (Date:4/23/2014)... Alzheimer,s disease is the first cause of dementia and ... effective cure has yet been found. One of the ... the cellular mechanisms which cause alterations in nerve transmissions ... of the disease., Researchers from the Institute of Neuroscience ... cellular mechanism involved in memory consolidation and were able ...
    (Date:4/23/2014)... University of Liverpool is leading a 2 million Food ... norovirus in food premises and industry workers. , ... In 2012 a batch of frozen strawberries infected ... in the authorities, understanding of which strains cause infection ... the bacteria. , Researchers will produce data ...
    (Date:4/22/2014)... the University of Montana,s Wildlife Biology Program, co-wrote a research ... National Academy of Sciences on how streamwater chemistry varies ... Lowe and ... of Washington, the Cary Institute of Ecosystem Studies, the University ... examined 664 water samples collected every 10 meters along 32 ...
    Breaking Biology News(10 mins):Loss of memory in Alzheimer's mice models reversed through gene therapy 2New research focuses on streamwater chemistry, landscape variation 2
    ... on a unique vertebrate called the sea lamprey shows that ... development. These genes are paradoxically lost all throughout the developing ... or PGCs. The PGCs can be thought of as embryonic ... generation of lampreys. Based on computational analysis, a significant number ...
    ... An inexpensive antifungal drug, thiabendazole, slows tumor growth and shows ... of Natural Sciences at The University of Texas at Austin ... frogs, mice and humans. Thiabendazole is an FDA-approved, generic ... 40 years as an antifungal. It is not currently used ...
    ... 2012) What comes naturally to most people to ... who have lost the full use of their limbs. New ... TIRR Memorial Hermann aims to help victims recover that ability ... from the National Institutes of Health (NIH) and the President,s ...
    Cached Biology News:Research reveals unique solution to gene regulation 2Common antifungal drug decreases tumor growth and shows promise as cancer therapy 2Brain-wave-reading robot might help stroke patients 2Brain-wave-reading robot might help stroke patients 3
    Rabbit polyclonal to HMGB1 (rating: ****) ( Abpromise for all tested applications). entrezGeneID: 3146 SwissProtID: P09429...
    Pooled normal sreum with 0.1% sodium azide as preservative...
    Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
    Mouse P-Selectin/CD62P MAb (Clone 127933)...
    Biology Products: